Table 1.
Explanatory variable | Metaregression coefficient [95% CI] | P | Datasets |
---|---|---|---|
Age (years) | 0.87 [−0.641, 2.390] | = 0.246 | 29 |
Females (%) | −0.241 [−1.078, 0.597] | = 0.561 | 32 |
Follow-up duration (months) | −0.037 [−0.735, 0.661] | = 0.914 | 29 |
% patients with TNM M0 | 0.018 [−0.276, 0.314] | = 0.892 | 14 |
% patients with TNM M1a | 1.201 [0.464, 1.938] | = 0.004 | 14 |
% patients with TNM M1b | 1.259 [0.414, 2.104] | = 0.007 | 14 |
% patients with TNM M1c | −0.857 [−1.251, −0.463] | <0.00001 | 19 |
% patients with brain metastasis | 0.043 [−0.219, 0.306] | = 0.736 | 23 |
% patients with 0 ECOG PS | 0.596 [0.133, 1.060] | = 0.014 | 23 |
% patients with 1 ECOG PS | −0.180 [−0.969, 0.610] | = 0.644 | 28 |
% patients with BRAF mutations | −0.110 [−0.565, 0.345] | = 0.622 | 26 |
% patients with high LDH levels | −0.355 [−0.777, 0.066] | = 0.094 | 26 |
% patients with PD-L1 positivity | 0.119 [−0.137, 0.375] | = 0.326 | 12 |
% patients with prior therapy | −0.240 [−0.392, −0.088] | = 0.003 | 32 |